Organoid Coculture Models for Cancer Research and Immunotherapy
Med Research, EarlyView.This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang +9 more
wiley +1 more source
Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAF(V600E) Tumors
, 2014 The RAS-RAF-MEK (MAP-ERK kinase)-ERK (extracellular signal-regulated kinase) pathway plays a central role in driving proliferation, survival, and metastasis signals in tumor cells, and the prevalence of oncogenic mutations in RAS and BRAF and upstream ...
Stuart, DD, Das Thakur, M
core
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
Medicinal Research Reviews, EarlyView.ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek +3 more
wiley +1 more source
NRAS Mutations in Different Melanoma Histotypes: Molecular and Clinical Implications. [PDF]
Curr Oncol RepPisano M +10 more
europepmc +1 more source
The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors
Medicinal Research Reviews, EarlyView.ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti +6 more
wiley +1 more source
Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma. [PDF]
Ann HematolKarim I +9 more
europepmc +1 more source
New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer. [PDF]
Cancer SciTreatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Takahashi M, Taniguchi SH, Yoshida Y.
europepmc +2 more sources
Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine
Medicinal Research Reviews, EarlyView.ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli +5 more
wiley +1 more source
Mechanisms of Resistance to MEK Inhibitors (RAS-MAPK Pathway) in Malignant Peripheral Nerve Sheath Tumors and Their Precursor Lesions (Plexiform Neurofibromas) Associated with Neurofibromatosis Type 1. [PDF]
Cancers (Basel)Sologov SI +10 more
europepmc +1 more source
, 2007 Mek Stans 07 is a machine developed for Tetra Pak in Lund as a 10p candidate theses project at Halmstad University. The commission behind the project involved development of a machine that punches holes in packages for the inspection division at Tetra Pak.
Lundgren, Andreas +2 more
openaire +1 more source